TITLE

Antiretroviral therapy of late presenters with advanced HIV disease

AUTHOR(S)
Manuel Battegay; Jan Fehr; Ursula Flückiger; Luigia Elzi
PUB. DATE
July 2008
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Jul2008, Vol. 62 Issue 1, p41
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Potent antiretroviral therapy (ART) has dramatically improved the prognosis of HIV-1-infected individuals. However, 10% to 30% of patients in Western countries still present late for care, when CD4 T cells are below 200 cells/mm3 and symptomatic HIV disease has occurred. Clinical considerations for advanced HIV disease are paramount as morbidity and mortality are directly correlated with a low initial CD4 T cell count, which is commonly associated with the simultaneous occurrence of co-morbidities, particularly opportunistic infections. Upon start of ART, the clinical entity of immune reconstitution inflammatory syndrome may occur and, in this context, raise the question of early versus delayed ART in patients treated for opportunistic infections. Recent data clearly indicate that an earlier start of ART is warranted in this latter situation. Guidelines for specific antiretroviral treatment for late-presenting patients are lacking. Knowledge about drug–drug interactions and co-morbidities should guide treatment choices and influence the clinical management and monitoring of drug-related side effects and interactions. Importantly, the outlook of patients who present late is very much dependent upon the initial response to ART. Nevertheless, even if optimal response to treatment has been achieved, long-term prognosis may be impaired in patients who initially presented with advanced HIV disease. We encourage physicians to perform HIV testing more frequently in order to detect HIV-infected individuals in time.
ACCESSION #
33053677

 

Related Articles

  • Predictors of Plasma Human Immunodeficiency Virus Type 1 RNA Control after Discontinuation of Highly Active Antiretroviral Therapy Initiated at Acute Infection Combined with Structured Treatment Interruptions and Immune-Based Therapies. Lafeuillade, A.; Poggi, C.; Hittinger, G.; Counillon, E.; Emilie, D. // Journal of Infectious Diseases;11/15/2003, Vol. 188 Issue 10, p1426 

    Identifies the predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. Achievement of viral control; Measurement...

  • The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review. Gates, Thomas; Cysique, Lucette; Gates, Thomas M; Cysique, Lucette A // CNS Drugs;Jan2016, Vol. 30 Issue 1, p53 

    HIV infection has become a chronic illness when successfully treated with combined antiretroviral therapy (cART). The long-term health prognosis of aging with controlled HIV infection and HIV-associated neurocognitive disorder (HAND) remains unclear. In this review, we propose that, almost 20...

  • Mortality in HIV-Seropositive versus -Seronegative Persons in the Era of Highly Active Antiretroviral Therapy: Implications for When to Initiate Therapy. Wang, Cunlin; Vlahov, David; Galai, Noya; Bareta, Joseph; Strathdee, Steffanie A.; Kenrad E. Nelson; Timothy R. Sterling // Journal of Infectious Diseases;9/15/2004, Vol. 190 Issue 6, p1046 

    Background. The optimal time to initiate highly active antiretroviral therapy (HAART) remains unclear. Methods. Five hundred eight-three human immunodeficiency virus (HIV)-seropositive and 920 HIV-seronegative injection drug users (IDUs) were followed from 1997 2000. HIV-seropositive...

  • Standing in the Way of Eradication: HIV-1 Infection and Treatment in the Male Genital Tract. Shehu-Xhilaga, Miranda; De Kretser, David; Dejucq-Rainsford, Nathalie; Hedger, Mark // Current HIV Research;Oct2005, Vol. 3 Issue 4, p345 

    As a result of the introduction of the Highly Active Antiretroviral Therapy (HAART) many HIV-1 infected individuals are able to live an improved and extended life style that can include the prospect of having children. Problematically, the male reproductive organs may contribute infected cells...

  • Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India. Tripathy, S.; Anand, A.; Inamdar, V.; Manoj, M. M.; Khillare, K. M.; Datye, A. S.; Iyer, R.; Kanoj, D. M.; Thakar, M.; Kale, V.; Pereira, M.; Risbud, A. R. // Indian Journal of Medical Research;May2011, Vol. 133 Issue 5, p521 

    Background & objectives: in the Revised National Tuberculosis Control Programme (RNTCP) in India prior to 2005, TB patients were offered standard DOTS regimens without knowledge of HIV status. Consequently such patients did not receive anti-retroviral therapy (ART) and the influence of...

  • Early drug therapy reduces HIV transmission, study says. Taylor, Billy // Pink Paper;5/13/2011, p1 

    The article offers information on the HIV Prevention Trials Network's controlled trial conducted across Africa, Asia and the Americas, known as HPTN 052, which shows that treating an HIV-positive person with anti-retroviral therapy can reduce the risk of sexual transmission of HIV to an...

  • Nevirapine.  // Reactions Weekly;10/23/2010, Issue 1324, p28 

    The article describes the case of a 40-year-old woman with HIV infection who presented with maculopapular exanthema following administration with an antiretroviral three-drug treatment plus levofloxacin, referencing a study presented at the 10th Annual Meeting of the International Society of...

  • EARLY START OF HIV DRUG TREATMENT SAVES LIVES.  // International Perspectives on Sexual & Reproductive Health;Sep2010, Vol. 36 Issue 3, p121 

    The article discusses research reported by P. Severe et al. in a 2010 issue of the "New England Journal of Medicine" on early initiation of antiretroviral therapy for HIV treatment.

  • Lopinavir/ritonavir.  // Reactions Weekly;3/10/2007, Issue 1142, p18 

    The article presents a case report of a man with human immunodeficiency virus (HIV) infection who developed hyponatremia during his treatment with lopinavir and ritonavir. The author states that a sudden decrease in the sodium level of the patient was probably caused by lopinavir. It mentions...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics